Andrew Brunner

Myelodysplastic syndromes are disorders of the bone marrow associated with bone marrow failure and a risk of progression to acute myeloid leukemia. My clinical area of focus and research projects are focused toward understanding treatment patterns and patient outcomes in MDS and other advanced hematologic malignancies, and to develop new treatments for these patients. The therapies available for patients with MDS have not changed in the last decade, and there is critical need to develop new agents and identify the patients most likely to benefit from a given chemotherapy. I am involved in clinical trials for all stages of MDS with an overall goal of tailoring treatment to improve the outcomes of these patients.

Departments, Centers, & Programs:

• Hematology/Oncology

Clinical Interests:

• Acute and Chronic Leukemia
• Acute Lymphocytic Leukemia
• Acute Myeloid Leukemia
• Chronic myeloid leukemia
• Myelodysplasia
• Myelodysplastic syndrome (MDS)
• Myeloproliferative neoplasms

Medical Education

• MD, Warren Alpert Medical School of Brown University
• Residency, Massachusetts General Hospital
• Fellowship, Brigham and Women's Hospital
• Fellowship, Dana Farber Cancer Institute
• Fellowship, Dana Farber Cancer Institute

American Board Certifications

• Internal Medicine, American Board of Internal Medicine
• Medical Oncology, American Board of Internal Medicine